SCHEDULE 13G 0001569064 XXXXXXXX LIVE Common Shares, CHF 0.10 nominal value per share 06/15/2021 0001745114 MOLECULAR PARTNERS AG 60853G106 Wagistrasse 14 Zurich-Schlieren V8 8952 Rule 13d-1(c) SUVRETTA CAPITAL MANAGEMENT, LLC b DE 0 4284806 0 4284806 4284806 N 10.6 IA OO Note in relation to Items 9 and 11: Includes 2,221,494 ADSs (as defined below), each of which represents one (1) Common Share (as defined below). Note in relation to Item 11: Based on 40,363,095 Common Shares outstanding as of December 31, 2024, as reported in the Issuer's (as defined below) annual report on Form 20-F filed with the Securities and Exchange Commission (the "SEC") on March 6, 2025. Averill Master Fund, Ltd. b E9 0 4284806 0 4284806 4284806 N 10.6 CO Note in relation to Items 9 and 11: Includes 2,221,494 ADSs, each of which represents one (1) Common Share. Note in relation to Item 11: Based on 40,363,095 Common Shares outstanding as of December 31, 2024, as reported in the Issuer's annual report on Form 20-F filed with the SEC on March 6, 2025. Aaron Cowen b X1 0 4284806 0 4284806 4284806 N 10.6 IN HC Note in relation to Items 9 and 11: Includes 2,221,494 ADSs, each of which represents one (1) Common Share. Note in relation to Item 11: Based on 40,363,095 Common Shares outstanding as of December 31, 2024, as reported in the Issuer's annual report on Form 20-F filed with the SEC on March 6, 2025. MOLECULAR PARTNERS AG Wagistrasse 14, Zurich-Schlieren, Switzerland, 8952 The persons filing this Schedule 13G are Averill Master Fund, Ltd., a Cayman Islands exempted company ("Averill Master Fund"), Suvretta Capital Management, LLC, a Delaware limited liability company ("Suvretta Capital"), and Aaron Cowen ("Mr. Cowen") (collectively, the "Reporting Persons"). The agreement among the Reporting Persons to file this Schedule 13G jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, is attached as Exhibit A hereto. The CUSIP provided in this statement is the CUSIP for the American Depositary Shares ("ADS") of Molecular Partners AG, incorporated as a Swiss Aktiengesellschaft, or AG (the "Issuer"). Each ADS represents one Common Share, CHF 0.10 nominal value per share ("Common Shares"). The address of the principal office of (i) Averill Master Fund is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands, and (ii) each of Suvretta Capital and Mr. Cowen is c/o Suvretta Capital Management, LLC, 540 Madison Avenue, 7th Floor, New York, New York, 10022. Averill Master Fund is a Cayman Islands exempted company. Suvretta Capital is a Delaware limited liability company. Mr. Cowen is a United States citizen. Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference herein. Mr. Cowen is the control person and managing member of Suvretta Capital and may be deemed to control Averill Master Fund. Mr. Cowen disclaims beneficial ownership of all Common Shares held by Averill Master Fund, other than, to the extent of any pecuniary interest therein. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that any Reporting Person or any of its affiliates is the beneficial owner of any Common Shares for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference herein. The percentage set forth in Row 11 of each Reporting Person's cover page is based on 40,363,095 Common Shares outstanding as of December 31, 2024, as reported in the Issuer's annual report on Form 20-F filed with the SEC on March 6, 2025. Suvretta Capital Management, LLC - 10.6% Aaron Cowen - 10.6% Averill Master Fund, Ltd. - 10.6 Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference herein. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference herein. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference herein. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. Y Y N Please see Exhibit B attached hereto. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. SUVRETTA CAPITAL MANAGEMENT, LLC /s/ Andrew Nathanson 05/02/2025 Averill Master Fund, Ltd. /s/ Andrew Nathanson 05/02/2025 Aaron Cowen /s/ Aaron Cowen 05/02/2025